From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors.

Authors

Gang Wang, Zhibin Tan, Wenting Jia, Yuanyuan Liu, Huan Wang, Wenbo Sun, Weiwei Sun, Lu Meng, Yudong Zhang, Ning Liu, Feng Li, Hongchao Dong

Published in

Frontiers in oncology. Volume 16. Pages 1880986. Epub Jul 20, 2026.

Abstract

Cancer remains a major global public health burden, with high morbidity and mortality. Despite advances in treatment strategies, many patients with advanced solid tumors face treatment resistance and limited therapeutic options. Patient-derived tumor organoids (PDTOs) have emerged as promising preclinical models for personalized medicine, but their clinical translational potential in guiding individualized treatment for advanced solid tumors requires further validation.
The sample data of 164 solid tumors used for establishing organoids were retrospectively analyzed, and a clinical cohort involving 23 patients with advanced solid tumors was used to validate the feasibility of PDTOs in predicting the treatment response. The concordance between PDTO drug responses and clinical outcomes was evaluated using Cohen's Kappa test.
The overall establishment success rate of organoids reached 91.5%, with the rates ranging from 90.6% to 92.6% across different cancer types. Histopathological analysis confirmed that PDTOs partially recapitulated the histopathological features and proliferative activity of matched original tumors. PDTO-based drug sensitivity testing showed good concordance with clinical treatment outcomes of patients with advanced solid tumors, yielding an overall accuracy of 85.0%, a sensitivity of 86.7%, a specificity of 80.0%. Clinical case studies further highlighted the unique value of PDTOs in overcoming multidrug resistance in advanced solid tumors.
This study demonstrates that PDTOs exhibit favorable potential for predicting treatment responses in patients with advanced solid tumors, and may serve as a promising auxiliary companion diagnostic tool to inform personalized cancer therapy and assist in evaluating multidrug resistance for advanced solid tumors. Future large-scale, multicenter studies with stratified subgroup validations are warranted to further verify the clinical translational value of PDTOs in individualized tumor treatment.

PMID:
42548623
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.